Pre-Exposure Prophylaxis (PrEP) is a daily medication that provides high levels of protection from HIV. The science is in on this one too. If taken as prescribed, PrEP can be a successful HIV prevention strategy, although it does not protect against STIs or pregnancy.

At the moment, there are three medications approved for use as PrEP in Australia; Truvada™ and two generic variants, produced by Mylan and Generic Health.

Generic medications approved for use work exactly the same way as their brand name counterparts – and all the clinical studies use them too. It’s all PrEP and it all works.

Although it isn’t currently available on the Pharmaceutical Benefits Scheme (PBS) there are PrEP demonstration projects (trials) that welcome trans men at risk of HIV infection.

PrEPX in Victoria
PrEPX-SA in South Australia
PrEPX-TAS in Tasmania
PrEPIT-WA in Western Australia
QPrEPd in Queensland

Anyone unable to access the study can import medication for personal use from overseas, with the cost of importing cheaper than ever before. Learn more about the personal importation scheme here.

Anyone unable to afford the cost of importing PrEP will be eligible for free PrEP through the PAN [PrEPaccessNOW] Assistance Scheme – head to the PAN website for more information.

Truvada has no known contraindications with any transition-related hormones such as Primotestin and Reandron. It is an HIV medication that many trans people living with HIV have used for treatment over many years.MNC-20160423-Pash-Syd-490-P12K

The current best expert opinion is that PrEP protects both front hole and anal penetration after 7 days. To maintain this protective level, people having receptive front hole sex need to keep taking Truvada daily, for people having receptive anal sex there is more flexibility, however, it is recommended that the medication be taken every day.

When and if you decide to stop taking Truvada as PrEP, make sure you keep taking it for 28 days after any risk event (such as condomless sex) before stopping the medication. This essentially turns PrEP into PEP and reduces the risk of seroconversion.

It’s also important to note that the HIV-negative partner in a serodiscordant relationship (i.e., where partners are of different statuses) where the HIV-positive person has an undetectable viral load is not eligible to participate in most of these Australian PrEP demonstration projects (except QLD) on the basis of having an HIV positive partner alone since the risk is so low.

Check out’s position paper on PrEP for trans men here and submission to the Pharmaceutical Benefits Advisory Council for the PBS listing of Truvada as PrEP here.

We were thrilled to work with the Victorian AIDS Council on this great video resource all about PrEP 4 trans men.